

Kluwer Patent Blog

Valsartan, Oslo District Court (Oslo tingrett), 10 February 2011

Kaja Veel Midtbø · Thursday, July 7th, 2011 · Landmark European Patent Cases

The Court, in infringement proceedings brought by Novartis against Actavis for marketing generic Valsartan, held that the assessment of infringement had to be made as of the time of infringement, not as of the priority date. This is the first decision in years in Norway taking a position on this issue. The judgement also deals with the scope of Novartis SPC for Valsartan, which the Court held to protect both mono products and combination products with Valsartan and hydrochlorotiazide.

Click [here](#) for the full text of this case.

A **full summary** of this case has been published on **Kluwer IP Law**.

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe [here](#).

Kluwer IP Law

The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how **Kluwer IP Law** can support you.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT
The Wolters Kluwer Future Ready Lawyer
Leading change



This entry was posted on Thursday, July 7th, 2011 at 11:59 am and is filed under [Case Law](#), literally fulfil all features of the claim. The purpose of the doctrine is to prevent an infringer from stealing the benefit of an invention by changing minor or insubstantial details while retaining the same functionality. Internationally, the criteria for determining equivalents vary. For example, German courts apply a three-step test known as *Schneidmesser's* questions. In the UK, the equivalence doctrine was most recently discussed in *Eli Lilly v Actavis UK* in July 2017. In the US, the function-way-result test is used.”>Equivalents, Norway, Scope of protection, SPC
You can follow any responses to this entry through the [Comments \(RSS\) feed](#). Both comments and pings are currently closed.